ClinConnect ClinConnect Logo
Search / Trial NCT06014112

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Aug 22, 2023

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Acute Coronary Syndrome Continuous Glucose Measurement Glycemic Variability Cardiovascular Event

ClinConnect Summary

This clinical trial is studying how different blood sugar levels and patterns, measured using a device called the Freestyle Libre Pro iQ, can predict heart-related events in patients with Acute Coronary Syndrome (ACS). ACS is a serious condition that can involve chest pain and heart problems. Researchers believe that monitoring blood sugar continuously for two weeks, rather than just measuring it once upon hospital admission, may give better insights into a patient’s risk for major heart issues over the next year.

To participate in this trial, individuals must be hospitalized for ACS in a cardiac intensive care unit and have specific signs like chest pain or changes in heart readings. Those who are critically ill from other conditions, like severe shock, or who are unable to provide informed consent, will not be eligible. Participants can expect to wear the glucose monitor for two weeks, during which their blood sugar levels will be recorded continuously. This study aims to improve the understanding of how blood sugar affects heart health in ACS patients, potentially leading to better care in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with ACS managed in a cardiac intensive care unit (ICU). The diagnosis of ACS will be made in the presence of chest pain with ST-segment elevation on the ECG for STEMI or ST-segment change and/or a positive troponin cycle (values in accordance with the center's protocol) for NSTEMI.
  • Exclusion Criteria:
  • Subjects in cardiogenic or septic shock
  • Subjects with ACS initially managed in a non-investigating center
  • Failure to obtain free, informed, written consent signed by the participant and investigator upon admission to the ICU
  • Person participating in another research study with an ongoing exclusion period
  • Subjects participating in a study that may have an impact on post ACS prognosis
  • Person deprived of his or her rights, person under guardianship or curatorship
  • Person deprived of liberty (by judicial or administrative decision)
  • Persons whose physical and/or psychological health is severely impaired, which, in the opinion of the investigator, may affect the participant's compliance to the study
  • Pregnant or breastfeeding women
  • Person who is not affiliated to a social security system or who is a beneficiary of such a system.

About University Hospital, Montpellier

The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.

Locations

Toulouse, , France

Montpellier, , France

Nîmes, , France

Bordeaux, , France

Béziers, , France

Pau, , France

Paris, , France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported